| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2019: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
Hepatocellular carcinoma is the second leading cause of cancer death worldwide. In this study, we performed the immunohistochemistry and flow cytometer analysis to identify the cellular heterogeneity of tumor as well as stromal cells. We further performed the single cell transcriptome analysis using peripheral blood mononuclear cells of hepatocellular carcinoma patients. We identified that tumor stromal cells expressing PD1 or CCR6 as well as tumor cells expressing CCL20 were mostly detected at the periphery, not the center of the tumor. We further identified the circulating cell population specifically detected in hepatocellular carcinoma patients. Interestingly, these cell population contained both tumor cells and stromal cells potentially regulating immune system. This study provides important molecular basis of circulating cells potentially be utilized for the diagnosis and treatment of hepatocellular carcinoma.
|
